CpG-ODN, the TLR9 agonist, attenuates myocardial ischemia/reperfusion injury: Involving activation of PI3K/Akt signaling

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 1, 2013, Pages 96-104

  Cao, Zhijuan ^a   Ren, Danyang ^a   Ha, Tuanzhu ^a   Liu, Li ^b   Wang, Xiaohui ^a   Kalbfleisch, John ^c   Gao, Xiang ^d   Kao, Race ^a   Williams, David ^a   Li, Chuanfu ^a  

^a East Tennessee State University   (United States)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c EAST TENNESSEE STATE UNIVERSITY   (United States)

^d NANJING UNIVERSITY   (China)

Author keywords

Apoptosis; Myocardial I R; PI3K Akt signaling; TLR9

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GLYCOGEN SYNTHASE KINASE 3BETA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P85; TOLL LIKE RECEPTOR 9;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEART FUNCTION; HEART INFARCTION SIZE; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; REPERFUSION INJURY; SIGNAL TRANSDUCTION; STAINING; TISSUE LEVEL;

ANIMALS; CELL LINE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOCARDIAL ISCHEMIA; OLIGODEOXYRIBONUCLEOTIDES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RATS; REPERFUSION INJURY; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 9;

MUS;

EID: 84868516625     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2012.08.008     Document Type: Article

References (37)

1. Aderem A., Ulevitch R.J. Toll-like receptors in the induction of the innate immune response. Nature 2000, 406:782-787.
2. Arslan F., Smeets M.B., O'Neill L.A., Keogh B., McGuirk P., Timmers L., Tersteeg C., Hoefer I.E., Doevendans P.A., Pasterkamp G., de Kleijn D.P. Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody. Circulation 2010, 121:80-90.
3. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657.
4. Chao W. Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart. Am. J. Physiol. Heart Circ. Physiol. 2009, 296:H12.
5. Chong A.J., Shimamoto A., Hampton C.R., Takayama H., Spring D.J., Rothnie C.L., Yada M., Pohlman T.H., Verrier E.D. Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart. J. Thorac. Cardiovasc. Surg. 2004, 128:170-179.
6. Dong J.W., Vallejo J.G., Tzeng H.P., Thomas J.A., Mann D.L. Innate immunity mediates myocardial preconditioning through Toll-like receptor 2 and TIRAP-dependent signaling pathways. Am. J. Physiol. Heart Circ. Physiol. 2010, 298:H1079-H1087.
7. Fujio Y., Nguyen T., Wencker D., Kitsis R.N., Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 2000, 101:660-667.
8. Fukao T., Koyasu S. PI3K and negative regulation of TLR signaling. Trends Immunol. 2003, 24:358-363.
9. Ha T., Hu Y., Liu L., Lu C., McMullen J.R., Shioi T., Isumo S., Kelley J., Kao R.L., Williams D.L., Gao X., Li C. TLR2 ligands induce cardioprotection against ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism. Cardiovasc. Res. 2010, 87:694-703.
10. Ha T., Hua F., Liu X., Ma J., McMullen J.R., Shioi T., Izumo S., Kelley J., Gao X., Browder W., Williams D.L., Kao R.L., Li C. Lipopolysaccharide-induced myocardial protection against ischemia/reperfusion injury is mediated through a PI3K/Akt-dependent mechanism. Cardiovasc. Res. 2008, 78:546-553.
11. Ha T., Lu C., Liu L., Hua F., Hu Y., Kelley J., Singh K., Kao R.L., Kalbfleisch J., Williams D.L., Gao X., Li C. TLR2 ligands attenuate cardiac dysfunction in polymicrobial sepsis via a phosphoinositide-3-kinase dependent mechanism. Am. J. Physiol. Heart Circ. Physiol. 2010, 298:H984-H991.
12. Hua F., Ha T., Ma J., Li Y., Kelley J., Gao X., Browder I.W., Kao R.L., Williams D.L., Li C. Protection against myocardial ischemia/reperfusion injury in TLR4 deficient mice is mediated through a phosphoinositide 3-kinase dependent mechanism. J. Immunol. 2007, 178:7317-7324.
13. Hua F., Ma J., Ha T., Kelley J., Williams D.L., Kao R.L., Kalbfleisch J.H., Browder I.W., Li C. Preconditioning with a TLR2 specific ligand increases resistance to cerebral ischemia/reperfusion injury. J. Neuroimmunol. 2008, 199:75-82.
14. Hyakkoku K., Hamanaka J., Tsuruma K., Shimazawa M., Tanaka H., Uematsu S., Akira S., Inagaki N., Nagai H., Hara H. Toll-like receptor 4 (TLR4), but not TLR3 or TLR9, knock-out mice have meuroprotective effects against focal cerebral ischemia. Neuroscience 2010, 171:258-267.
15. Jozsef L., Khreiss T., Filep J.G. CpG motifs in bacterial DNA delay apoptosis of neutrophil granulocytes. FASEB J. 2004, 18:1776-1778.
16. Knuefermann P., Schwederski M., Velten M., Krings P., Ehrentraut H., Rudiger M., Boehm O., Fink K., Dreiner U., Grohe C., Hoeft A., Baumgarten G., Koch A., Zacharowski K., Meyer R. Bacterial DNA induces myocardial inflammation and reduces cardiomyocyte contractility: role of toll-like receptor 9. Cardiovasc. Res. 2008, 78:26-35.
17. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 2006, 5:471-484.
18. Kumagai Y., Takeuchi O., Akira S. TLR9 as a key receptor for the recognition of DNA. Adv. Drug Deliv. Rev. 2008, 60:795-804.
19. Li C., Ha T., Kelley J., Gao X., Qiu Y., Kao R.L., Browder W., Williams D.L. Modulating Toll-like receptor mediated signaling by (1->3)-b-D-glucan rapidly induces cardioprotection. Cardiovasc. Res. 2003, 61:538-547.
20. Lim E.J., Park D.W., Lee J.G., Lee C.H., Bae Y.S., Hwang Y.C., Jeong J.W., Chin B.R., Baek S.H. Toll-like receptor 9-mediated inhibition of apoptosis occurs through suppression of FoxO3a activity and induction of FLIP expression. Exp. Mol. Med. 2010, 42:712-720.
21. Mathur S., Walley K.R., Boyd J.H. The Toll-like receptor 9 ligand CPG-C attenuates acute inflammatory cardiac dysfunction. Shock 2011, 36:478-483.
22. Matsui T., Ling L., del Monte F., Fukui Y., Franke T.F., Hajjar R.J., Rosenzweig A. Adenoviral gene transfer of activated phosphatidylinositol 3'-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation 1999, 100:2373-2379.
23. McCubrey J.A., Steelman L.S., Chappell W.H., Abrams S.L., Wong E.W.T., Chang F., Lehmann B., Terrian D.M., Milella M., Tafuri A., Stivala F., Libra M., Basecke J., Evangelisti C., Martelli A.M., Franklin R.A. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta 2007, 1773:1263-1284.
24. Mersmann J., Berkels R., Zacharowski P., Tran N., Koch A., Lekushi K., Dimmeler S., Granja T.F., Boehm O., Claycomb W.C., Zacharowski K. Preconditioning by toll-like receptor 2 agonist Pam3CSK4 reduces CXCL1-dependent leukocyte recruitment in murine myocardial ischemia/reperfusion injury. Crit. Care Med. 2010, 38:903-909.
25. Ojaniemi M., Glumoff V., Harju K., Liljeroos M., Vuori K., Hallman M. Phosphatidylinositol 3-kinase is involved in Toll-like receptor 4-mediated cytokine expression in mouse macrophages. Eur. J. Immunol. 2003, 33:597-605.
26. Oyama J., Blais C., Liu X., Pu M., Kobzik L., Kelly R.A., Bourcier T. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 2004, 109:784-789.
27. Rice L., Orlow D., Ceonzo K., Stahl G.L., Trianabos A.O., Wada H., Aird W.C., Buras J.A. CpG oligodeoxynucleotide protection in polymicrobial sepsis is dependent on interleukin-17. J. Infect. Dis. 2005, 191:1368-1376.
28. Sakata Y., Dong J.-W., Vallejo J.G., Huang C.-H., Baker J.S., Tracey K.J., Tacheuchi O., Akira S., Mann D.L. Toll-like receptor 2 modulates left ventricular function following ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 2007, 292:H503-H509.
29. Sester D.P., Brion K., Trieu A., Goodridge H.S., Roberts T.L., Dunn J., Hume D.A., Stacey K.J., Sweet M.J. CpG DNA activates survival in murine macrophages through TLR9 and the phosphatidylinositol 3-kinase-Akt pathway. J. Immunol. 2006, 177:4473-4480.
30. Shimamoto A., Chong A.J., Yada M., Shomura S., Takayama H., Fleisig A.J., Agnew M.L., Hampton C.R., Rothnie C.L., Spring D.J., Pohlman T.H., Shimpo H., Verrier E.D. Inhibition of Toll-like receptor 4 with Eritoran attenuates myocardial ischemia-reperfusion injury. Circulation 2006, 114:I-270-I-274.
31. Shioi T., McMullen J.R., Kang P.M., Douglas P.S., Obata T., Franke T.F., Cantley L.C., Izumo S. Akt/protein kinase B promotes organ growth in transgenic mice. Mol. Cell. Biol. 2002, 22:2799-2809.
32. Stevens S.L., Ciesielski T.M., Marsh B.J., Yang T., Homen D.S., Boule J.L., Lessov N.S., Simon R.P., Stenzel-Poore M.P. Toll-like receptor 9: a new target of ischemic preconditioning in the brain. J. Cereb. Blood Flow Metab. 2008, 28:1040-1047.
33. Vollmer J., Krieg A.M. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv. Drug Deliv. Rev. 2009, 61:195-204.
34. Weighardt H., Feterowski C., Veit M., Rump M., Wagner H., Holzmann B. Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response. J. Immunol. 2000, 165:4537-4543.
35. Williams D.L., Ozment-Skelton T., Li C. Modulation of the phosphoinositide-3-kinase signaling pathway alters host resistance to sepsis, inflammation, and ischemia/reperfusion injury. Shock 2006, 25:432-439.
36. Yang L., Guo W., Zhang Q., Li H., Liu X., Yang Y., Zuo J., Liu W. Crosstalk between Raf/MEK/ERK and PI3K/AKT in suppression of Bax conformational change by Grp75 under glucose deprivation conditions. J. Mol. Biol. 2011, 414:654-666.
37. Zhang X., Gao M., Ha T., Kalbfleisch J.H., Browder W., Williams D.L., Li C., Kao R.L. The TLR9 agonist, CpG-ODN 1826, ameliorates cardiac dysfunction after trauma-hemorrhage. Shock 2012, 38:146-152.